Specialized care program for end-stage heart failure patients. Initial experience in a heart failure unit;Programa de atención especializada en la insuficiencia cardíaca terminal. Experiencia piloto de una unidad de insuficiencia cardíaca

Revista Espanola de Cardiologia

Volumn 59, Issue 2, 2006, Pages 109-116

  Roig, Eulàlia ^a   Pérez Villa, Félix ^a   Cuppoletti, Alfredo ^a   Castillo, Magdalena ^a   Hernández, Nuria ^a   Morales, Manel ^a   Betriu, Amadeo ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cardiomyopathy; Follow up studies; Heart failure; Transplantation

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CREATININE; DIGOXIN; ENALAPRIL; FUROSEMIDE; HEMOGLOBIN; LOSARTAN; SODIUM; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST CONTROL; CREATININE BLOOD LEVEL; DAY CARE; DEATH; DEFIBRILLATOR; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH CARE COST; HEART EJECTION FRACTION; HEART FAILURE; HEART TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HOME CARE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT EDUCATION; SODIUM BLOOD LEVEL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

EID: 33645563905     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13084637     Document Type: Article

References (38)

1. Zannad F, Briancon S, Juilliere Y, Mertes PM, Villemot JP, Alla F, et al, and the EPICAL Investigators. Incidence, clinical and etiologic features and outcomes of advanced chronic heart failure: The EPICAL study. J Am Coll Cardiol. 1999;33:734-42.
2. Brotons C, Moral I, Ribera A, Pérez G, Cascant P, Bustins M, et al. Tendencias de la morbimortalidad por IC en Cataluña. Rev Esp Cardiol. 1998;51:972-6.
3. Stewart S, MacItyre K, Hole D, Capewell S, McMurray J. More malignant than cancer? Five year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3:315-22.
4. Kittleson M, Hurwitz S, Shah M, Nohria A, Lewis E, Givertz M, et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol. 2003;41:2029-35.
5. Stewart S, Jenkins A, Buchan S, McGuire A, Capwell S, McMurray J. The current cost of heart failure to the national health service in the UK. Eur J Heart Fail. 2002;4:361-71.
6. Rich M, Beckham V, Wittenberg C, Leven C, Freedland K, Carney A. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190-5.
7. Riegel B, Carlson B, Glaser D, Hoagland P. Which patients with Herat failure respond best to multidisciplinary disease management? J Card Fail. 2000;6:290-9.
8. Gonseth J, Guallar-Castillón P, Banegas J, Rodríguez-Artalejo F. The effectiveness of disease management programmes in reducing hospital re-admission in older patients with Heart failure: a systematic review and meta-analysis of published reports. Eur Heart J. 2004;25:1570-95.
9. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348: 2007-18.
10. Almenar L, en representación de los grupos españoles de trasplante cardíaco. Registro Español de Trasplante Cardíaco. XV Informe Oficial de la Sección de IC, Trasplante Cardíaco y otras alternativas terapéuticas de la Sociedad Española de Cardiología (1984-2003). Rev Esp Cardiol. 2004;57:1197-204.
11. Upadya S, Lee F, Saldarriaga C, Verma S, Sedrakyan A, Nystrom K, et al. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. J Heart Lung Transplant. 2004;23:466-72.
12. Lindelöw B, Andersson B, Waagstein F, Bergh C. Prognosis of alternative therapies in patients with heart failure not accepted for heart transplantation. J Heart Lung Transplant. 1995;14:1204-11.
13. Swedberg K, Cleland J, Dargie H, Drexler H, Follath, Komajda M, et al. Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida (actualización 2005). Rev Esp Cardiol. 2005;58:1062-92.
14. Lupón J, Altimir S, González B, Urrutia A, Coll R, Prats M, et al. Geriatric evaluation of all patients in a new multidisciplinary unit. Eur J Heart Fail. 2002;1 Suppl: 30.
15. West J, Miller N, Parker K, Senneca D, Ghandour G, Clark M, et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol. 1997;79:58-63.
16. McAlister F, Stewart S, Ferrua S, McMurray J. Multidisciplinary strategies for the management of heart failure patients at high risk for admission. J Am Coll Cardiol. 2004;44:810-9.
17. Fonarow G, Stevenson L, Walden J, Livingston N, Steimle A, Hamilton M, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol. 1997;30: 725-32.
18. Lupón J, Pajarón T, Urrutia A, González B, Herreros J, Altimir S, et al. Reducción de los ingresos por IC en el primer año de seguimiento en una unidad multidisciplinaria. Rev Esp Cardiol. 2005; 58:374-80.
19. Hershberger R, Ni H, Nauman D, Burgess D, Toy W, Wise K, et al. Prospective evaluation of an outpatient heart failure management program. J Card Fail. 2001;7:64-74.
20. Gustafsson F, Arnold JM. Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. Eur Heart J. 2004;25:1596-604.
21. Hershberger R, Nauman D, Walker T, Dutton D, Burgess D. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail. 2003;9:180-7.
22. Rose E, Gelijns A, Moskowitz A, Heitjan D, Stevenson L, Dembitsky W, et al. for the randomised evaluation of mechanical assistance for the treatment of congestive heart failure (REMATCH) study group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435-43.
23. Stewart S, Horowitz D. Home-based intervention in congestive heart failure long-term implications on readmission and survival. Circulation. 2002;105:2861-6.
24. Kasper E. A randomised trial of the efficacy of multidisciplinary care in heart failure. Outpatients at high risk of hospital readmission. J Am Coll Cardiol. 2002;39:471-80.
25. O'Connor C, Gattis W, Uretsky B, Adams K, McNulty S, Grossman S, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan international randomized survival trial (FIRST). Am Heart J. 1999;138:78-86.
26. Felker GM, Benza R, Chandler B, Leimberger J, Cuffe M, Califf R, et al, for the OPTIME-CHF investigators. Heart failure etiology and response to milrinone in decompensated heart failure. J Am Coll Cardiol. 2003;41:997-1003.
27. Stevenson L, Miller L, Desving-Nickens P, Ascheim D, Parides M, Renlund D, et al, for the REMATCH investigators. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy. Circulation. 2004;110:975-81.
28. Stevenson L. Inotropic therapy for heart failure. N Engl J Med. 1998;339:1848-50.
29. DICE Collaborative Group: ambulatory intermittent 6-month low-dose dobutamine infusion in severe heart failure. Instituto M Negri. J Am Coll Cardiol. 1997;30:132A.
30. Friedman A, Silver S, Minella R, Lipman R. An overview of intermittent inotropic therapy for severe congestive heart failure. Congest Heart Fail. 1999;5:63-73.
31. Freimark D, Feinberg M, Matezky S, Hochberg N, Shechter M. Impact of short-term intermittent intravenous dobutamine therapy on endothelial function in patients with severe chronic heart failure. Am Heart J. 2004;148:878-82.
32. Nieminen M, Böhm M, Cowie M, Drexler H, Filippatos G, Jondean G, et al. Guías de práctica clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca aguda. Versión resumida. Rev Esp Cardiol. 2005;58:389-429.
33. Brozena S, Twomey C, Goldberg L, Desai S, Drachman B, Kao A, et al. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. J Heart Lung Transplant. 2004;23:1082-6.
34. Packer M, Poole-Wilson P, Armstrong P, Cleland J, Horowitz J, Massie B, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril on morbidity and mortality in chronic heart failure. ATLAS study group. Circulation. 1999;100:2312-8.
35. Nohria A, Tsang S, Fang J, Lewis E, Jarcho J, Mudge G, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797-804.
36. Spear G. Eosinophilic explant carditis with eosinophilia: hypersensitivity to dobutamine infusion. J Heart Lung Transplant. 1995;14:755-60.
37. Gravanis M, Hertzler G, Franch R, Stacy L, Ansari A, Kanter K, et al. Hypersentivity myocarditis in heart transplant candidates. J Heart Lung Transplant. 1991;10:688-97.
38. Nanas J, Papazoglou P, Terrovitis J, Kanakakis J, Dalianis A, Tsolakis E, et al. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol. 2004;94:1329-32.